Trial · NCT02395822
MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
NCT02395822, Phase 2, Completed, Masonic Cancer Center, University of Minnesota; results first posted 2018-01-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients. Trials, record NCT02395822. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02395822
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients
- NCT number
- NCT02395822
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 17 participants, actual
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- IL-15
- First posted
- 2015-03-24
- Last updated
- 2018-02-20
- Results first posted
- 2018-01-10
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L | Day 42 post NK cell infusion | Without platelet recovery |
| Secondary | In Vivo Expansion (>100) of NK Cells (Defined at CD56+/CD3- Lymphocytes) | Day 14 post NK cell infusion | |
| Secondary | Proportion of Patients Experiencing Grade, 3, 4, and 5 Toxicities (Assessed by CTCAE v. 4) | Days 1-5 and Days 8-12, 24 hours after the last IL-15 dose, Day +28, Day +42 | |
| Secondary | Treatment Related Mortality | 6 months post-therapy | |
| Secondary | Number of Subjects Achieving Complete Response, Defined as in Vivo Donor Derived NK Cell Expansion of > 100 Donor Derived NK Cells. | Day 42 post NK cell infusion |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L | Day 42 post NK cell infusion | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | In Vivo Expansion (>100) of NK Cells (Defined at CD56+/CD3- Lymphocytes) | Day 14 post NK cell infusion | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Proportion of Patients Experiencing Grade, 3, 4, and 5 Toxicities (Assessed by CTCAE v. 4) | Days 1-5 and Days 8-12, 24 hours after the last IL-15 dose, Day +28, Day +42 | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Treatment Related Mortality | 6 months post-therapy | 1 patient left the study | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Subjects Achieving Complete Response, Defined as in Vivo Donor Derived NK Cell Expansion of > 100 Donor Derived NK Cells. | Day 42 post NK cell infusion | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group5
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| < 5% Marrow Blast, no Circulating Peripheral Blasts and Neutrophil Count of > 1 x 10^9/L | Preparative Regimen and SubQ rHuIL-15 | 5 | Participants | ||
| In Vivo Expansion (>100) of NK Cells (Defined at CD56+/CD3- Lymphocytes) | Preparative Regimen and SubQ rHuIL-15 | 4 | Participants | ||
| Proportion of Patients Experiencing Grade, 3, 4, and 5 Toxicities (Assessed by CTCAE v. 4) | Preparative Regimen and SubQ rHuIL-15 | 10 | Participants | ||
| Treatment Related Mortality | Preparative Regimen and SubQ rHuIL-15 | 2 | Participants | ||
| Number of Subjects Achieving Complete Response, Defined as in Vivo Donor Derived NK Cell Expansion of > 100 Donor Derived NK Cells. | Preparative Regimen and SubQ rHuIL-15 | 1 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Preparative Regimen and SubQ rHuIL-15 | 17 | |
| Overall Study | COMPLETED | Preparative Regimen and SubQ rHuIL-15 | 15 | |
| Overall Study | NOT COMPLETED | Preparative Regimen and SubQ rHuIL-15 | 2 |
Source ClinicalTrials.gov
Adverse events51
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acute kidney injury | Renal and urinary disorders | Preparative Regimen and SubQ rHuIL-15 | 2 | 17 | |
| other | Alanine aminotransferase increased | Investigations | Preparative Regimen and SubQ rHuIL-15 | 1 | 17 | |
| other | Aspartate aminotransferase increased | Investigations | Preparative Regimen and SubQ rHuIL-15 | 1 | 17 | |
| other | Back pain | Musculoskeletal and connective tissue disorders | Preparative Regimen and SubQ rHuIL-15 | 1 | 17 | |
| other | Blood bilirubin increased | Investigations | Preparative Regimen and SubQ rHuIL-15 | 1 | 17 | |
| other | Chest wall pain | Musculoskeletal and connective tissue disorders | Preparative Regimen and SubQ rHuIL-15 | 1 | 17 | |
| other | Confusion | Psychiatric disorders | Preparative Regimen and SubQ rHuIL-15 | 4 | 17 | |
| other | Creatinine increased | Investigations | Preparative Regimen and SubQ rHuIL-15 | 1 | 17 | |
| other | Cytokine release syndrome | Immune system disorders | Preparative Regimen and SubQ rHuIL-15 | 5 | 17 | |
| other | Encephalopathy | Nervous system disorders | Preparative Regimen and SubQ rHuIL-15 | 2 | 17 |
1 to 10 of 51Source ClinicalTrials.gov
See all 51 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Preparative Regimen and SubQ rHuIL-15 | ||
| Total, other adverse events | Preparative Regimen and SubQ rHuIL-15 | 15 | 17 |
| Total, serious adverse events | Preparative Regimen and SubQ rHuIL-15 | 12 | 17 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 31266741 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02395822
GET https://conductscience.org/api/trials/v1/NCT02395822/events?page=2